Full text is available at the source.
Abstract
A single dose of intravenous ketamine is being evaluated for its effects on depression and suicidality in adolescents with treatment-resistant depression.
- Adolescents often present to emergency departments for behavioral health emergencies, highlighting a gap in immediate treatment options.
- Prolonged boarding in emergency departments without treatment is common due to national staffing shortages and limited inpatient resources.
- Ketamine is recognized as a rapid-acting antidepressant in adults, but its effectiveness in suicidal youth remains under-researched.
- This evaluation compares the impacts of ketamine to placebo specifically for adolescents presenting with suicidal thoughts.
Simplified